Benzodiazepines and tinnitus: short-term benefit, long-term concern

Benzodiazepines occupy an unusual position in tinnitus management. They are occasionally used to reduce the distress and sleep disruption that severe tinnitus causes, and some patients report noticeable short-term relief. At the same time, tolerance, dependence, and a well-documented withdrawal syndrome that itself includes tinnitus as a symptom create significant long-term concerns. Understanding this tension is important for anyone with tinnitus who is currently taking or being offered a benzodiazepine.

How benzodiazepines work in the nervous system

Benzodiazepines enhance the effect of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. They bind to GABA-A receptors and increase the frequency with which chloride channels open in response to GABA binding. The result is a broad reduction in neuronal excitability across the brain, producing anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects.

From a tinnitus perspective, there are two relevant properties. First, the auditory system, including the cochlear nucleus and inferior colliculus in the brainstem, contains GABA-A receptors. In animal models, tinnitus is associated with reduced GABAergic inhibition in these auditory nuclei. Second, the limbic system, which processes emotional responses and distress, is also strongly modulated by GABA. Benzodiazepines may dampen both the central auditory hyperactivity and the emotional reaction to tinnitus.

Short-term benefit: what the evidence shows

Small clinical studies and case series have reported that benzodiazepines, particularly clonazepam, can reduce perceived tinnitus loudness and distress over periods of a few weeks. A frequently cited study by Bahmad and colleagues found that clonazepam reduced tinnitus loudness and annoyance in patients with unilateral tinnitus over a 90-day period.

These findings are suggestive but limited. Most tinnitus pharmacology trials have small sample sizes and lack long-term follow-up. Placebo response rates in tinnitus trials are consistently high, which makes it difficult to attribute improvements solely to the drug. The AAO-HNS 2014 clinical practice guideline did not recommend benzodiazepines as a standard treatment, noting insufficient high-quality evidence to support routine prescription.

In clinical practice, benzodiazepines are more commonly used to manage the acute distress and sleep disruption that accompanies severe tinnitus onset, rather than as a long-term therapeutic strategy. Their role, when used at all, is typically short-term bridging while other approaches such as cognitive behavioral therapy or sound therapy are established.

The tolerance problem

A central difficulty with benzodiazepines is that their benefits diminish with regular use. GABA-A receptors downregulate in response to chronic benzodiazepine exposure, meaning the brain compensates by reducing receptor sensitivity. Within weeks to months of daily use, the same dose produces less anxiolytic and sedative effect, and patients often require escalating doses to maintain initial relief.

For tinnitus patients, this means that the short-term distress reduction tends to erode, leaving the tinnitus perception unchanged while the patient now has a physiological dependence to manage. This trajectory makes long-term benzodiazepine use for tinnitus a poor strategy for most patients.

Withdrawal tinnitus

One of the most important concerns for tinnitus patients specifically is that benzodiazepine withdrawal can cause or intensify tinnitus. When benzodiazepines are stopped after regular use, the downregulated GABA-A receptor system becomes relatively under-inhibited, producing a rebound hyperexcitability. Symptoms of this withdrawal syndrome include anxiety, insomnia, sensory hypersensitivity, and tinnitus.

The severity of withdrawal depends on the duration of use, the specific drug, and how rapidly the drug is discontinued. Long-acting benzodiazepines like diazepam tend to produce a more gradual withdrawal syndrome than short-acting agents like alprazolam. NHS guidance on benzodiazepine dependence consistently recommends a slow, supervised taper rather than abrupt cessation to minimize withdrawal symptoms.

For a patient who started benzodiazepines because of tinnitus distress, experiencing intensified tinnitus during withdrawal creates a painful clinical situation. The withdrawal tinnitus can be mistaken for a worsening of the original condition, sometimes leading patients to seek reinstatement of the drug rather than continuing the taper.

Cognitive and safety considerations

Beyond dependence and withdrawal, regular benzodiazepine use is associated with several adverse effects that are particularly relevant for tinnitus patients:

Cognitive effects: Benzodiazepines impair attention, memory consolidation, and psychomotor speed. For tinnitus patients already experiencing concentration difficulties (a commonly reported effect of chronic tinnitus), adding a drug that further impairs cognitive function can compound the quality-of-life burden.

Sleep architecture: While benzodiazepines facilitate sleep onset and reduce night waking, they alter sleep architecture by suppressing slow-wave and REM sleep. Tinnitus is closely tied to sleep quality, and poor-quality sleep can amplify tinnitus perception. The net effect on sleep-related tinnitus burden is therefore complex.

Fall risk: Older adults taking benzodiazepines have substantially increased fall risk. Because presbycusis and tinnitus are more common with age, older tinnitus patients are disproportionately represented among those who might receive these prescriptions, making this consideration especially relevant.

What alternatives offer

The strongest evidence-based approaches for tinnitus distress do not involve benzodiazepines. Cognitive behavioral therapy for tinnitus has the most robust evidence base for reducing tinnitus-related distress and improving quality of life. Sound therapy, including sound masking and acoustic enrichment, addresses the perceptual dominance of tinnitus without pharmacological side effects. For patients with comorbid anxiety, SSRI or SNRI antidepressants have a more favorable long-term risk profile than benzodiazepines, though they carry their own evidence-related considerations for tinnitus.

These alternatives require more time and patient engagement than taking a pill, which partly explains why benzodiazepine prescriptions continue in this population despite clinical guideline caution. The AAO-HNS guideline strongly recommends clinicians counsel patients on evidence-based options before and instead of pharmacological treatments with limited evidence.

For patients currently taking benzodiazepines

Anyone taking a benzodiazepine regularly for tinnitus-related distress should discuss the long-term plan with their prescriber. Specifically, it is reasonable to ask how long use is intended, what the tapering plan is, and what adjunctive treatments can be started to reduce dependence on the benzodiazepine for coping with tinnitus.

Stopping a benzodiazepine abruptly after more than a few weeks of regular use carries seizure risk and severe withdrawal symptoms. Discontinuation should always be managed with medical supervision, typically through a graduated dose reduction over weeks to months depending on the duration of use.

If symptoms persist or change, see an audiologist or physician.